Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics, Inc. (CATX)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss on disposal of property and equipment | NaN | 0 | NaN | NaN |
| Net loss | -26,189 | -37,490 | -25,969 | -39,662 |
| Net accretion of discounts on available-for-sale securities | -490 | -400 | -558 | -1,765 |
| Foreign currency adjustments | NaN | -250 | NaN | NaN |
| Loss on divestiture | NaN | 0 | NaN | NaN |
| Depreciation and amortization expense | 1,126 | 1,011 | 775 | 1,465 |
| Goodwill impairment | NaN | 0 | NaN | NaN |
| Accrued interest on held-to-maturity investments | NaN | NaN | 0 | 0 |
| In-process research and development impairment | NaN | 10,000 | NaN | NaN |
| Share-based compensation | 2,553 | 2,309 | 2,156 | 4,501 |
| Deferred income tax benefit | NaN | -793 | NaN | NaN |
| Other noncash income, net | -78 | 231 | -14 | -222 |
| Accounts receivable | 52 | -173 | -46 | 109 |
| Inventory related to discontinued operations (note 4) | NaN | 0 | NaN | NaN |
| Interest receivable | 392 | -163 | 19 | 286 |
| Inventory | NaN | NaN | 0 | 0 |
| Prepaid expenses and other current assets | 327 | -375 | 10 | -259 |
| Accounts payable and accrued expenses | -4,213 | -846 | 5,541 | -4,548 |
| Deferred income | 0 | 0 | 0 | -1,400 |
| Accrued personnel expenses | -3,613 | 778 | 1,674 | -441 |
| Other noncurrent liabilities | 51 | 44 | 58 | 229 |
| Net cash used in operating activities | -31,468 | -24,657 | -16,292 | -41,535 |
| Additions to property and equipment | 6,858 | 5,075 | 1,992 | 5,682 |
| Proceeds from the sale of property and equipment | NaN | 0 | NaN | NaN |
| Additions to other assets | 0 | 51 | 39 | 45 |
| Proceeds from maturity of held-to-maturity investments | NaN | 0 | NaN | NaN |
| Purchases of held-to-maturity investments | NaN | 0 | 0 | 0 |
| Proceeds from held-to-maturity securities | NaN | NaN | 0 | 0 |
| Purchases of available-for-sale securities | 150,336 | 20,613 | 32,131 | 67,094 |
| Maturities of available-for-sale securities | 47,641 | 54,276 | 48,154 | 71,520 |
| Net cash used in investing activities | -109,553 | 28,537 | 13,992 | -1,301 |
| Repayment of note payable | 15 | 13 | 13 | 26 |
| Proceeds from sales of common stock, pursuant to exercise of warrants, net | NaN | 0 | 0 | 0 |
| Proceeds from sales of common stock, pursuant to exercise of options | 290 | 0 | 226 | 145 |
| Proceeds from the issuance of common stock and pre-funded warrants, net | NaN | NaN | 0 | 0 |
| Proceeds from the sales of common stock and pre-funded warrants, net | NaN | 0 | NaN | NaN |
| Proceeds from the sale of common stock pursuant to at-the-market offering, net | NaN | NaN | 0 | 9,986 |
| Proceeds from the issuance of common stock pursuant to the atm, net | NaN | 9,986 | NaN | NaN |
| Proceeds from issuance of common stock and pre-funded warrants, net | 164,089 | NaN | NaN | NaN |
| Net cash provided by financing activities | 164,364 | -13 | 213 | 10,105 |
| Net increase (decrease) in cash and cash equivalents | 23,343 | 3,867 | -2,087 | -32,731 |
| Cash and cash equivalents at beginning of period | 30,629 | 26,762 | 61,580 | NaN |
| Cash and cash equivalents at end of period | 53,972 | 30,629 | 26,762 | NaN |